Here's why the Immutep (ASX:IMM) share price is frozen

The company's shares will remain in a trading halt until Monday or pending a further update.

| More on:
a doctor looking up at question marks

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

For the second day in a row, the Immutep Ltd (ASX: IMM) share price will be frozen at market open.

Yesterday, Immutep entered a trading halt until Monday's open, or until such time as the company releases further news regarding a capital raise, whichever comes first.

When Immutep shares closed on Wednesday ­– their latest active session ­– they were swapping hands for 62 cents apiece.

Let's take a look at what we know so far of the biotechnology company's capital raise.

New capital raise

According to Immutep, the capital raise will be an institutional placement. However, the company has not yet stated how much it hopes to raise during the activity.

Additionally, Immutep hasn't yet disclosed why it will be conducting the capital raise.

Market watchers will be keeping an eye on the company today, as further details of its latest placement are likely to be announced before Monday's open.

The last institutional placement completed by Immutep took place in August 2020. Through that placement, the company raised $29.6 million by issuing 123.3 million new shares at 24 cents per share to institutional investors.

Immutep's previous capital raise was used to boost its clinical programs budget.

It mostly went towards the ongoing development of the company's IMP123 – a drug that regulates the immune system. However, a portion of the capital raised went towards Immutep's immunosuppressive agonist drug IMP761, which is still in preclinical stages.

Immutep share price snapshot

2021 has been a good year on the ASX so far for Immutep shares.

The Immutep share price is currently 48% higher than it was at the start of this year. It has also gained 305% since this time last year.

The company has a market capitalisation of around $444 million, with approximately 648 million shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »